Armistice Capital LLC Invests $96,000 in GRI Bio, Inc. (NASDAQ:GRI)

Armistice Capital LLC purchased a new stake in shares of GRI Bio, Inc. (NASDAQ:GRI) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 50,207 shares of the company’s stock, valued at approximately $96,000. Armistice Capital LLC owned about 9.23% of GRI Bio at the end of the most recent quarter.

GRI Bio Stock Down 10.2 %

NASDAQ:GRI opened at 0.45 on Friday. The stock’s 50 day simple moving average is 0.63 and its two-hundred day simple moving average is 3.68. GRI Bio, Inc. has a 1 year low of 0.40 and a 1 year high of 161.98.

GRI Bio (NASDAQ:GRI) last released its quarterly earnings results on Tuesday, August 13th. The company reported -4.92 EPS for the quarter.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.